CGEN
Price
$2.47
Change
+$0.01 (+0.41%)
Updated
Sep 11 closing price
Capitalization
234.72M
65 days until earnings call
Intraday BUY SELL Signals
DBVT
Price
$11.85
Change
-$1.12 (-8.64%)
Updated
Sep 11 closing price
Capitalization
825.94M
Intraday BUY SELL Signals
Interact to see
Advertisement

CGEN vs DBVT

CGEN vs DBVT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CGEN vs. DBVT commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and DBVT is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DBVT($826M) has a higher market cap than CGEN($235M). CGEN YTD gains are higher at: 61.438 vs. DBVT (-38.185). CGEN has higher annual earnings (EBITDA): 30.7M vs. DBVT (-166.22M). DBVT has more cash in the bank: 175M vs. CGEN (125M). CGEN has less debt than DBVT: CGEN (3.02M) vs DBVT (7.7M). CGEN has higher revenues than DBVT: CGEN (74M) vs DBVT (0).
CGENDBVTCGEN / DBVT
Capitalization235M826M28%
EBITDA30.7M-166.22M-18%
Gain YTD61.438-38.185-161%
P/E Ratio6.55N/A-
Revenue74M0-
Total Cash125M175M71%
Total Debt3.02M7.7M39%
FUNDAMENTALS RATINGS
CGEN vs DBVT: Fundamental Ratings
CGEN
DBVT
OUTLOOK RATING
1..100
7552
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2099
PRICE GROWTH RATING
1..100
3963
P/E GROWTH RATING
1..100
27100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DBVT's Valuation (42) in the Biotechnology industry is in the same range as CGEN (58). This means that DBVT’s stock grew similarly to CGEN’s over the last 12 months.

DBVT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CGEN (100). This means that DBVT’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (20) in the Biotechnology industry is significantly better than the same rating for DBVT (99). This means that CGEN’s stock grew significantly faster than DBVT’s over the last 12 months.

CGEN's Price Growth Rating (39) in the Biotechnology industry is in the same range as DBVT (63). This means that CGEN’s stock grew similarly to DBVT’s over the last 12 months.

CGEN's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for DBVT (100). This means that CGEN’s stock grew significantly faster than DBVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENDBVT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 10 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
85%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (CGEN: $2.47 vs. DBVT: $11.85)
Brand notoriety: CGEN and DBVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 58% vs. DBVT: 841%
Market capitalization -- CGEN: $234.72M vs. DBVT: $825.94M
CGEN [@Biotechnology] is valued at $234.72M. DBVT’s [@Biotechnology] market capitalization is $825.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 2 FA rating(s) are green while DBVT’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 2 green, 3 red.
  • DBVT’s FA Score: 0 green, 5 red.
According to our system of comparison, CGEN is a better buy in the long-term than DBVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 3 TA indicator(s) are bullish while DBVT’s TA Score has 5 bullish TA indicator(s).

  • CGEN’s TA Score: 3 bullish, 5 bearish.
  • DBVT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DBVT is a better buy in the short-term than CGEN.

Price Growth

CGEN (@Biotechnology) experienced а -4.63% price change this week, while DBVT (@Biotechnology) price change was -12.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

CGEN is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CGEN
Daily Signal:
Gain/Loss:
DBVT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DGFAX32.680.10
+0.31%
Davis Global A
FTEIX16.88N/A
N/A
Fidelity Advisor Total Intl Equity I
VSMCX11.72N/A
N/A
Invesco Small Cap Value C
MINVX29.53N/A
N/A
Madison Large Cap Y
GRERX8.48N/A
N/A
Goldman Sachs Real Estate Securities R

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with ORMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
+0.41%
ORMP - CGEN
40%
Loosely correlated
-2.10%
MLTX - CGEN
37%
Loosely correlated
-5.08%
AXON - CGEN
36%
Loosely correlated
+0.10%
NBTX - CGEN
36%
Loosely correlated
-1.57%
RCUS - CGEN
36%
Loosely correlated
-5.97%
More

DBVT and

Correlation & Price change

A.I.dvisor tells us that DBVT and GPCR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DBVT and GPCR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DBVT
1D Price
Change %
DBVT100%
-8.64%
GPCR - DBVT
32%
Poorly correlated
-2.25%
CRDF - DBVT
32%
Poorly correlated
N/A
RXRX - DBVT
31%
Poorly correlated
+1.27%
CGEN - DBVT
31%
Poorly correlated
+0.41%
KYMR - DBVT
30%
Poorly correlated
-1.74%
More